Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

ProKidney Q1 2024 Earnings Report

ProKidney logo
$1.50 -0.02 (-1.32%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

ProKidney EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q1 2024
Date
5/10/2024
Time
N/A

Conference Call Resources

Powered by Quartr

ProKidney Earnings Headlines

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm
January 31, 2025 | prnewswire.com
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
January 31, 2025 | seekingalpha.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
US Penny Stocks: 3 Picks With Market Caps Under $300M
January 27, 2025 | uk.finance.yahoo.com
ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site
January 24, 2025 | bizjournals.com
Cautiously Optimistic: ProKidney’s Hold Rating Amid Accelerated Pathway and Trial Developments
January 16, 2025 | markets.businessinsider.com
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

View ProKidney Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles